**Table 1.** Baseline Characteristics

|  |  |  |
| --- | --- | --- |
| **Parameter** | **A10(N=30)**  Mean± SD | **A10+CFP(N=30)**  Mean± SD |
| Age(year) | 49.40±4.94 | 47.83±5.65 |
| Weight(Kg) | 87.90±8.31 | 87.57±8.16 |
| LDL-C(mg/dl) | 152.55±22.4 | 153.25±23.1 |
| Total-C(mg/dl) | 232.6±24.5 | 238.54±28.1 |
| HDL-C(mg/dl) | 36.7±8.5 | 39.13±13.14 |
| TG(mg/dl) | 218.8±68.5 | 227.77±103.34 |
| ALT(U/L) | 33.17±10.67 | 31.71±10.15 |
| AST(U/L) | 26.53±6.95 | 23.17±6.63 |

**Table2**. Changes in lipid profile within and between the studied groups

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Parameter  Group | Total-C(mg/dl)  Mean± SD | *P value* | LDL-C(mg/dl)  Mean± SD | *P value* | HDL-C(mg/dl)  Mean± SD | *P*  *value* | TG(mg/dl)  Mean± SD | *P value* |
| Differences within the treatment groups | | | | | | | | |
| **A10** | | | | | | | | |
| **Baseline vs. 4th week** | -29.11±2.73 | <0.001 | -26.18±2.44 | <0.001 | 1±0.42 | NS | -21.63±4.7 | <0.001 |
| **4th week vs. 8th week** | -6.12±1.31 | <0.001 | -3.87±0.96 | 0.001 | 0.6±0.5 | NS | -5.8±2.9 | NS |
| **Baseline vs. 8th week** | -35.22±3.11 | <0.001 | -30.05±2.46 | <0.001 | 0.4±0.68 | NS | -27.4±6.63 | <0.001 |
| **A10+CFP** | | | | | | | | |
| **Baseline vs. 4th week** | -48.92±4.39 | <0.001 | -38.45±3.66 | <0.001 | -0.23±1.87 | NS | -48.13±13.1 | 0.003 |
| **4th week vs. 8th week** | -12.47±2.1 | <0.001 | -12.15±1.55 | <0.001 | -0.8±0.3 | NS | -7.57±3.75 | NS |
| **Baseline vs. 8th week** | -61.39±5.12 | <0.001 | -50.6±4.12 | <0.001 | 0.57±1.9 | NS | -55.7±15.4 | 0.003 |
| Differences between the treatment groups | | | | | | | | |
| **A10 vs. A10+CFP** | | | | | | | | |
| **Baseline** | NS | | NS | | NS | | NS | |
| **At 4th week** | NS | | 0.01 | | NS | | NS | |
| **At 8th week** | <0.001 | | <0.001 | | NS | | NS | |
| **p value†** | <0.001 | | <0.001 | | 0.008 | | <0.001 | |

NS: not statistically significant; A10: group receiving 10 mg/day atorvastatin; A10+CFP: group receiving 10 mg/day atorvastatin plus caper fruit pickle

†Comparison of differences among groups assessed by ANOVA

**Table 3**. Changes in liver enzyme tests over the course of the study

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Parameter  Group | ALT(mg/dl)  Mean± SD | *P value* | AST(mg/dl)  Mean± SD | *P value* |
| Changes within the treatment groups | | | | |
| **A10** | | | | |
| **Baseline *vs*. 4th week** | -0.07±0.95 | NS | -0.1±0.61 | NS |
| **4th week *vs*. 8th week** | 2.4±0.62 | 0.002 | 0.5±0.55 | NS |
| **Baseline *vs*. 8th week** | 2.33±1.35 | NS | 0.4±0.82 | NS |
| **A10+CFP** | | | | |
| **Baseline *vs.* 4th week** | -4.64±1.3 | 0.004 | 0.49±0.77 | NS |
| **4th week *vs.* 8th week** | -1.57±0.87 | NS | 0.43±0.64 | NS |
| **Baseline *vs.* 8th week** | -6.21±1.94 | 0.01 | 0.93±1.14 | NS |
| Differences between the treatment groups | | | | |
| **A10 vs. A10+CFP** | | | | |
| **Baseline** | NS | | NS | |
| **At 4th week** | NS | | NS | |
| **At 8th week** | NS | | NS | |
| **ANOVA†** | 0.04 | | NS | |

NS: not statistically significant; A10: group receiving 10 mg/day atorvastatin; A10+CFP: group receiving 10 mg/day atorvastatin plus caper fruit pickle

†Comparison of differences among groups assessed by ANOVA